China Tracker - Details for Sinobiopharma (SNBP)


Warning: fopen(http://finance.yahoo.com/d/quotes.csv?s=SNBP&f=snl1a2xf6): failed to open stream: HTTP request failed! HTTP/1.0 403 Forbidden in /home/fixyou/public_html/tracker_details.php on line 58

Warning: fgetcsv() expects parameter 1 to be resource, boolean given in /home/fixyou/public_html/tracker_details.php on line 60

Warning: fclose() expects parameter 1 to be resource, boolean given in /home/fixyou/public_html/tracker_details.php on line 61
 WARNING: Form 15 filed with the SEC!
 Sinobiopharma
Shares Outstanding (MRQ): 117.59 mill
New Shares / Dilution (TTM): 13.47 mill12.94% 
Cash (MRQ): 0.83 mill3.21%
Account Receivables (MRQ): 1.44 mill5.56%
Account Receivables (Q/Q): + 0.97 mill  
Long-Term Debt (MRQ): NO DEBT
Revenue Growth (Q/Q): 201.13% 
Revenue Growth (Y/Y): 101.59%
Net Income Growth (Q/Q): 2,423.90% 
Net Income Growth (Y/Y): 57.71%
EPS Growth (Y/Y): 39.64%
Net Margin (Q/Q): 36.9% (4.4%)32.50% 
Net Margin (Y/Y): 36.9% (47.2%)-10.30% 
EPS | P/E (2 MRQ Projection): $0.038.38
CFPS | P/CF (2 MRQ Projection): $0.028.84
Price/Sales (2 MRQ Projection): 2.42 
Price/Book (MRQ): 2.11 
Auditor: Marcum Bernstein & Pinchuk 
 
 Forward Projections (Fiscal Year)
EPS | P/E (Estimates updated 2011-04-21): $0.037.33
 Basic Facts and History (show more)
Reporting Type: U.S. Company (10-K Filings) 
Going Public: Reverse Merger on 2008-08-19 

 Business Outlook

Going Private (Effective Date: November 23, 2011). Every share of the Company common stock, issued and outstanding immediately prior to the Effective Date, will be converted into the right to receive $0.22 in cash.

(Source: 8-K Filing, 2011-11-21)

Sinobiopharma is pleased to announce thatin the first calendar quarter of 2010 it has signed 30 distribution contracts with distribution agents totaling US$8.4 million for 2010 for distribution of its flagship product KuTai. "We expect that revenue and net profit will increase considerably in 2010, not only because of our marketing efforts, but also because healthcare reform is accelerating the growth of market demand for pharmaceuticals."

(Source: Globe Newswire, 2010-07-06)

On July 1, 2010, the Board of Directors of Sinobiopharma, Inc. (the “Company”) approved the establishment of an Audit, Compensation, and Nominating Committee and adopted a Code of Ethics. The Company's Audit Committee now comprises three independent board members, namely, Du Wang (Chairman), Hoki Luk, and Yuanwei Chen. The Company's Compensation Committee similarly comprises three independent board members, namely, Yuanwei Chen (Chairman), Eric Shi and Hoki Luk. The Company's Nominating Committee also comprises three independent board members, namely Yuanwei Chen (Chairman), Du Wang and Eric Shi.

(Source: 8-K Filing, 2010-07-02)

 Analyst Coverage (show more)
2009-11-19Zacks Equity ResearchInitiationOutperform$0.80

 Investor Presentations
2010-10-01 (PDF)   DOWNLOAD (right click, save as)
2010-07-01 (HTML)   VIEW
SNBP
Healthcare & Drugs

COVERAGE SUSPENDED OR TERMINATED
 
READ: Score Cards Explained
SAFETY/RISK SCORE
MODERATE RISK
DETAILS: Safety/Risk Model for SNBP
Current Price:  $0.22
F10k Day (2008-12-05): -83.71%$1.35
2009 Close: 0.00%$0.22
2010 Close: -24.14%$0.29
High (2011-08-11): 0.00%$0.22
Low (2011-11-14): 175.00%$0.08
Exchange: PRIVATE
Market Capitalization: 25.87 mill
Total Shares: 117.59 mill
Float: n/a
Avg Volume: n/a
Last Quarter: 2011-02-28
Revenue (MRQ): 4.02 mill
Net Income (MRQ): 1.48 mill
Op. Cash Flow (MRQ): 0.74 mill
all financial data provided without warranty